3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
33
Breast Neoplasms
26
Triple Negative Breast Neoplasms
17
Prostatic Neoplasms
16
Fallopian Tube Neoplasms
11
Neoplasms
9
Fanconi Anemia, Complementation Group D1
7
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Glioma
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Osteosarcoma
3
Lung Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinosarcoma
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Interventions
Paclitaxel
7
Pemetrexed
3
Cisplatin
3
Carboplatin
3
pembrolizumab
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Radiotherapy
2
Nivolumab
2
FANG vaccine
2
Docetaxel
2
CP protocol
2
Brachytherapy
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olaparib
1
niraparib
1
larotrectinib
1
ipatasertib
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Neoplasms
×
olaparib
×
Clear all
NCT03951415
2021-04-01
DOMEC
Leiden University Medical Center
Phase 2
Unknown
55 enrolled